SV

Street Verdict

Analyst Scorecard

A record of what Tushar Manudhane said publicly, with the source. Not advice.

“The proposed US tariffs on generic imports, which are not India-specific, are unlikely to significantly impact Indian pharma. Manufacturing in India is 40-60% cheaper, and setting up US plants would take 3-4 years for approvals, making it economically unviable for generics. This implies minimal long-term impact on the Indian Pharma sector, despite initial market reaction.”
Nifty PharmaNeutralCalled 22 Jul 2026
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Tushar Manudhane’s full track record